Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 813-818

  Behre, Ulrich ^a   Bleckmann, Gerhard ^b   Crasta, Priya Diana ^c   Leyssen, Maarten ^d   Messier, Marc ^d   Jacquet, Jeanne Marie ^d   Hardt, Karin ^d  

^a Pediatric Practice   (Germany)

^b Kinder und Jugendarzt   (Germany)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Anti HBs; Hepatitis B; Immune memory; Long term; Persistence

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADOLESCENT HEALTH; AGE DISTRIBUTION; ARTICLE; BACKACHE; CHILD; CHILD HEALTH CARE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMATOMA; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; LONG TERM CARE; MALE; MASS IMMUNIZATION; SCHOOL CHILD; VERTIGO;

ADOLESCENT; CHILD; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; VACCINATION;

EID: 84863648282     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19898     Document Type: Article

References (22)

1. World Health Organization (WHO). Position paper, Hepatitis B. Wkly Epidemiol Rec 2009; 84:405-20; PMID:19817017.
2. Gabbuti A, Romanò L, Blanc P, Meacci F, Amendola A, Mele A, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25:3129-32; PMID:17291637; http:// dx.doi.org/10.1016/j.vaccine.2007.01.045.
3. Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection 2010; 38:395-400; PMID:20589522; http://dx.doi.org/10.1007/s15010-010-0039-7.
4. Poovorawan Y, Theamboonlers A, Hirsch P, Vimolket T, Sinlaparatsamee S, Chaiear K, et al. Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand. Ann Trop Med Parasitol 2000; 94:615-21; PMID:11064763.
5. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26:6266-73; PMID:18848855; http://dx.doi.org/10.1016/j.vaccine.2008.09.056.
6. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, et al.; Study Group. Longterm immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84; PMID:16226616; http://dx.doi. org/10.1016/S0140-6736(05)67568-X.
7. Duval B, Gîlca V, Boulianne N, De Wals P, Massé R, Trudeau G, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005; 24:213-8; PMID:15750456; http://dx.doi.org/10.1097/01. inf.0000154329.00361.39.
8. van der Sande MAB, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006; 193:1528-35; PMID:16652281; http://dx.doi.org/ 10.1086/503433.
9. European consensus group on hepatitis B immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-5; PMID:10683019; http://dx.doi.org/10.1016/S0140-6736(99)07239-6.
10. Banatvala JE, Van Damme P. Hepatitis B vaccine - do we need boosters? J Viral Hepat 2003; 10:1-6; PMID:12558904; http://dx.doi.org/10.1046/j.1365-2893. 2003.00400.x.
11. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011; 18:369-75; PMID:20384962; http://dx.doi.org/10.1111/j.1365-2893.2010.01312.x.
12. Romano L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011; 43:2-7; PMID:21195368; http://dx.doi.org/10.1016/S1590-8658(10)60685-8.
13. Van Damme P. Hepatitis B: vaccination programmes in Europe - an update. Vaccine 2001; 19:2375-9; PMID:11257363; http://dx.doi.org/10.1016/S0264-410X(00) 00457-6.
14. Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, et al. Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later. Vaccine 2009; 27:6048-53; PMID:19683086; http://dx.doi.org/10.1016/j. vaccine.2009.07.100.
15. Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, et al. Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine. Hum Vaccin 2010; 6:212-8; PMID:19946212; http:// dx.doi.org/10.4161/hv.6.2.10299.
16. Heininger U, Sänger R, Jacquet JM, Schuerman L; DTP-HBV-IPV-059 Study Group; DTP-HBVIPV-096 Study Group. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25:1055-63; PMID:17049692; http://dx.doi.org/10.1016/j. vaccine.2006.09.060.
17. Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa- HBV-IPV/Hib vaccine. Hum Vaccin 2009; 5:592-8; PMID:19535920.
18. Zinke M, Disselhoff J; the DTPa-HBV-IPV-110 and -111 study groups, Gartner B, Jacquet JM. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin 2010; 6:189-93; http://dx.doi.org/10.4161/hv.6.2.10117.
19. Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/ Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10:9; PMID:20078876; http://dx.doi. org/10.1186/1471-2334-10-9.
20. Harbarth S, Szucs T, Berger K, Jilg W. The economic burden of hepatitis B in Germany. Eur J Epidemiol 2000; 16:173-7; PMID:10845268; http://dx.doi. org/10.1023/A:1007624415699.
21. Lobstein S, Faber R, Tillmann HL. Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. Digestion 2011; 83:76-82; PMID:21042018; http://dx.doi. org/10.1159/000320455.
22. Cambron P, Jacquet JM, Hoet B, Lievens M. Development, technical and clinical validation of a quantitative 2 ELISA for the detection of human antibodies to Hepatitis B surface 3 antigen (HBsAg) in recipients of recombinant HBV vaccine. Clin Vaccine Immunol 2009; 16:1236-46; PMID:19553553; http://dx.doi.org/10.1128/CVI.00431-08.